Home›Trial›NCT07373639
🔬NCT07373639RECRUITING

A Long-term Follow-up Study in Patients Who Received BEAM-101

Study Summary

This is a Long-term Follow-up (LTFU) study in patients who received BEAM-101 in the parent study (Study BTX-AUT-001). Eligible patients who received BEAM-101 will be asked to participate in this LTFU study prior to completing Study BTX-AUT-001. Patients who enter into this study will be followed for 13 years (a total of 15 years after receiving BEAM-101).

Conditions
HemoglobinopathySickle Cell Disease
Interventions / Drugs
Long-Term Follow-up Study of patients who received BEAM-101
View on ClinicalTrials.gov ↗
Sponsor
BEAM
Beam Therapeutics
Base Editing
B71/100
Study Details
Enrollment50 participants
Primary Completion—
Lead SponsorBeam Therapeutics Inc.
Data Retrieved2026-04-11 04:07:17.424746+00:00
Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.